Short Interest in Tharimmune, Inc. (NASDAQ:THAR) Expands By 37.4%

Tharimmune, Inc. (NASDAQ:THAR) was the target of a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 89,300 shares, an increase of 37.4% from the November 30th total of 65,000 shares. Based on an average daily volume of 1,230,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 6.2% of the company’s stock are short sold.

Analyst Ratings Changes

A number of research firms recently commented on THAR. Rodman & Renshaw initiated coverage on Tharimmune in a report on Friday, December 6th. They issued a “buy” rating and a $17.00 price objective on the stock. RODMAN&RENSHAW raised shares of Tharimmune to a “strong-buy” rating in a research report on Friday, December 6th.

Hedge Funds Weigh In On Tharimmune

An institutional investor recently bought a new position in Tharimmune stock. Curi RMB Capital LLC acquired a new position in Tharimmune, Inc. (NASDAQ:THAR) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 23,620 shares of the company’s stock, valued at approximately $59,000. Curi RMB Capital LLC owned approximately 2.06% of Tharimmune as of its most recent SEC filing. 1.16% of the stock is owned by institutional investors.

Tharimmune Trading Down 4.2 %

Shares of THAR traded down $0.09 on Friday, reaching $2.06. 144,086 shares of the company’s stock were exchanged, compared to its average volume of 348,641. The business has a 50 day moving average price of $2.29 and a two-hundred day moving average price of $2.72. Tharimmune has a 12 month low of $1.84 and a 12 month high of $8.42.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).